Last reviewed · How we verify
PF-07850327, ARV-471, vepdegestrant (pf-07850327-arv-471-vepdegestrant)
PF-07850327, ARV-471, and vepdegestrant are investigational drugs being developed by Pfizer Inc. These compounds are in various stages of clinical development for the treatment of hormone receptor-positive breast cancer. PF-07850327 is a selective estrogen receptor degrader (SERD), while ARV-471 is a next-generation SERD, and vepdegestrant is an oral selective estrogen receptor covalent antagonist (SERCA). The drugs aim to improve upon existing treatments by offering better efficacy and safety profiles. Clinical trials are ongoing to evaluate their safety and effectiveness.
At a glance
| Generic name | pf-07850327-arv-471-vepdegestrant |
|---|---|
| Sponsor | Pfizer |
| Drug class | Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs) |
| Target | Estrogen Receptor (ER) |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer
- Hormone receptor-positive breast cancer
- Breast cancer with a PIK3CA mutation
- Breast cancer with a PIK3CA mutation and hormone receptor-positive
- Breast cancer with a PIK3CA mutation and HER2-negative
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, and HER2-negative
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, and ESR1 mutation
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, and ESR1 mutation and/or TP53 mutation
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, and/or TP53 mutation
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, and/or CDK4/6 inhibitor resistance
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, and/or prior endocrine therapy
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, and/or prior chemotherapy
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, and/or prior radiotherapy
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy
- Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane
Pipeline indications
Common side effects
Drug interactions
- PF-07850327
- ARV-471
- Vepoloxamer
- PF-07850327
- ARV-471
- Vepoloxamer
- PF-07850327
- ARV-471
- Vepoloxamer
- PF-07850327
- ARV-471
- Vepoloxamer
Key clinical trials
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (PHASE3)
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) (PHASE1, PHASE2)
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. (PHASE1, PHASE2)
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer (PHASE3)
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) (PHASE1, PHASE2)
- A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function (PHASE1)
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) (PHASE1, PHASE2)
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07850327, ARV-471, vepdegestrant CI brief — competitive landscape report
- PF-07850327, ARV-471, vepdegestrant updates RSS · CI watch RSS
- Pfizer portfolio CI